Analysis of 4 single-nucleotide polymorphisms in relation to cervical dysplasia and cancer development using a high-throughput ligation-detection reaction procedure

International Journal of Gynecological Cancer

Volumn 21, Issue 9, 2011, Pages 1664-1671

  Von Keyserling, Helmut ^a   Bergmann, Thomas ^b   Schuetz, Miriam ^a   Schiller, Ursula ^a   Stanke, Jonas ^a   Hoffmann, Corinna ^a   Schneider, Achim ^a   Lehrach, Hans ^b   Dahl, Andreas ^b   Kaufmann, Andreas M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

Cervical cancer; CYP1A1; CYP2E1; HPV; MTHFR; P53 and TP53

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; PROTEIN P53; CYP1A1 PROTEIN, HUMAN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; UTERINE CERVIX DYSPLASIA; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOLOGY; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84857398832     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31822b6299     Document Type: Article

References (32)

1. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207-225. (Pubitemid 43380597)
2. Moscicki AB. Conservative management of adolescents with abnormal cytology and histology. J Natl Compr Cancer Netw. 2008;6:101-106.
3. Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature. 1999;400:29-30.
4. Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609-1621.
5. Appleby P, Beral V, Berrington de Gonzalez A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118:1481-1495.
6. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer. 2001;84:1219-1226. (Pubitemid 32511340)
7. Agorastos T, Koutkias V, Falelakis M, et al. Semantic integration of cervical cancer data repositories to facilitate multicenter association studies: the ASSIST approach. Cancer informatics. 2009;8:31-44.
8. Borodina TA, Lehrach H, Soldatov AV. Ligation detection reaction-TaqMan procedure for single nucleotide polymorphism detection on genomic DNA. Anal Biochem. 2004;333:309-319. (Pubitemid 39278054)
9. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331. (Pubitemid 27131374)
10. Piyathilake CJ, Azrad M, Macaluso M, et al. Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. Nutrition (Burbank, Los Angeles County, Calif). 2007;23:229-235.
11. van der Put NM, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet. 1995;346:1070-1071.
12. Agodi A, Barchitta M, Cipresso R, et al. Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in Sicily. Int J Gynecol Cancer. 2010;20:141-146.
13. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001;58:737-747. (Pubitemid 32553031)
14. Uematsu F, Kikuchi H, Motomiya M, et al. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn J Cancer Res. 1991;82:254-256.
15. Ferreira PM, Medeiros R, Vasconcelos A, et al. Association between CYP2E1 polymorphisms and susceptibility to prostate cancer. Eur J Cancer Prev. 2003;12:205-211. (Pubitemid 36683757)
16. Kim JW, Lee CG, Park YG, et al. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relation to the incidence rate of cervical carcinoma. Cancer. 2000;88:2082-2091. (Pubitemid 30233210)
17. Sierra-Torres CH, Au WW, Arrastia CD, et al. Polymorphisms for chemical metabolizing genes and risk for cervical neoplasia. Environ Mol Mutagen. 2003;41:69-76. (Pubitemid 36159625)
18. Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res. 1999;424:127-142. (Pubitemid 29101614)
19. Goodman MT, McDuffie K, Hernandez B, et al. CYP1A1, GSTM1, and GSTT1 polymorphisms and the risk of cervical squamous intraepithelial lesions in a multiethnic population. Gynecol Oncol. 2001;81:263-269. (Pubitemid 32424172)
20. de Roda Husman AM, Walboomers JM, van den Brule AJ, et al. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995;76:1057-1062.
21. Schmitt M, Dondog B, Waterboer T, et al. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol. 2008;46:1050-1059. (Pubitemid 351380000)
22. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229-234. (Pubitemid 28261713)
23. Klug SJ, Ressing M, Koenig J, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10:772-784.
24. Goodman MT, McDuffie K, Hernandez B, et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev. 2001;10:1275-1280. (Pubitemid 34027759)
25. Powers HJ. Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and cervical cancer. J Nutr. 2005;135:2960S-2966S. (Pubitemid 43156573)
26. Henao OL, Piyathilake CJ, Waterbor JW, et al. Women with polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) are less likely to have cervical intraepithelial neoplasia (CIN) 2 or 3. Int J Cancer. 2005;113:991-997. (Pubitemid 40096879)
27. Delgado-Enciso I, Martinez-Garza SG, Rojas-Martinez A, et al. The effect of MTHFR polymorphisms, pregnancy and first intercourse on cervical cancer in a population from the Northeastern Mexico [Article in Spanish]. Rev Invest Clin. 2006;58:462-469. (Pubitemid 46380614)
28. Lambropoulos AF, Agorastos T, Foka ZJ, et al. Methylenetetrahydrofolate reductase polymorphism C677T is not associated to the risk of cervical dysplasia. Cancer Lett. 2003;191:187-191. (Pubitemid 36255604)
29. Sull JW, Jee SH, Yi S, et al. The effect of methylenetetrahydrofolate reductase polymorphism C677T on cervical cancer in Korean women. Gynecol Oncol. 2004;95:557-563. (Pubitemid 39592521)
30. Agorastos T, Papadopoulos N, Lambropoulos AF, et al. Glutathione-S- transferase M1 and T1 and cytochrome P1A1 genetic polymorphisms and susceptibility to cervical intraepithelial neoplasia in Greek women. Eur J Cancer Prev. 2007;16:498-504. (Pubitemid 350307498)
31. Juárez-Cedillo T, Vallejo M, Fragoso JM, et al. The risk of developing cervical cancer in Mexican women is associated to CYP1A1 MspI polymorphism. Eur J Cancer. 2007;43:1590-1595. (Pubitemid 46891804)
32. Ferreira PM, Catarino R, Pereira D, et al. Cervical cancer and CYP2E1 polymorphisms: implications for molecular epidemiology. Eur J Clin Pharmacol. 2006;62:15-21. (Pubitemid 43106311)